RT Journal Article SR Electronic T1 Case of e-cigarette or vaping product use-associated lung injury (EVALI) in London, UK JF BMJ Case Reports JO BMJ Case Reports FD BMJ Publishing Group Ltd SP e240700 DO 10.1136/bcr-2020-240700 VO 14 IS 4 A1 Ruth Elizabeth Evans A1 Sophie Herbert A1 William Owen A1 Deepak Rao YR 2021 UL http://casereports.bmj.com/content/14/4/e240700.abstract AB We present a case of a 38-year-old man with no medical comorbidities who presented to the hospital with haemoptysis and shortness of breath on a background of vaping home-manufactured cannabis oil. He developed e-cigarette or vaping product use-associated lung injury (EVALI) visible on chest X-ray requiring oxygen, and corticosteroid treatment before making a recovery. Research reports that the contents vitamin E acetate and tetrahydrocannabinol are frequently found in substances acquired from informal sources which increase the likelihood of EVALI developing. Further research into their synergistic effect is ongoing. Although safer than smoking, vaping is not risk free and EVALI should be considered in patients presenting with respiratory disease.